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Background: Nrf2 has been implicated in regulating immune cell signaling and function.
Results: Nrf2-deficient murine DCs exhibit enhanced maturation phenotype, increased ROS levels with dysregulation of
antigen uptake capabilities, and altered intracellular signaling.
Conclusion: Nrf2 regulates DC intracellular redox and immune function.
Significance:Defining the role of Nrf2 in DC biology underpins development of potential Nrf2 targeted immunotherapeutics.
Dendritic cells (DCs) are critical mediators of immunity and
immune tolerance by orchestrating multiple aspects of T cell
activation and function. Immature DCs (iDCs) expressing low
levels of co-stimulatory receptors are highly efficient at antigen
capture but are poor activators of T cells. Maturation of DCs is
associated with increased expression of co-stimulatory mole-
cules. Co-stimulatory receptor gene expression is regulated by
intracellular redox, NF-B, andMAPKpathways and by histone
deacetylase (HDAC) activity. The transcription factor, Nrf2, is
important for maintaining intracellular glutathione (GSH) lev-
els and redox homeostasis and has been implicated in modulat-
ingDCco-stimulatory receptor expression. It is unclearwhether
Nrf2 mediates this effect by GSH-dependent mechanisms and
whether it influences DC signaling pathways. Using bone mar-
row-derived iDCs from Nrf2/ and Nrf2/mice, we demon-
strate that Nrf2/ iDCs have lower basal GSH levels, enhanced
co-stimulatory receptor expression, impaired phagocytic func-
tions, and increased antigen-specific CD8 T cell stimulation
capacity. Interestingly, loweringGSH levels inNrf2/ iDCs did
not recapitulate the Nrf2/ iDC phenotype. Loss of Nrf2
resulted in elevated basal levels of reactive oxygen species but
did not affect basal NF-B activity or p38 MAPK phosphoryla-
tion. Using pharmacological inhibitors, we demonstrate that
enhanced co-stimulatory receptor phenotype of Nrf2/ iDC
does not require ERK activity but is dependent on HDAC activ-
ity, indicating a potential interaction betweenNrf2 function and
HDAC. These results suggest that Nrf2 activity is required to
counter rises in intracellular reactive oxygen species and to reg-
ulate pathways that control DC co-stimulatory receptor
expression.
Dendritic cells (DCs)4 are potent antigen-presenting cells
that are responsible for orchestrating immune responses (1).
DCs reside in the periphery in an immature antigen-capturing
state, enabling them to survey the environment for the presence
of soluble antigens, microbes, and dying cells (2, 3). Immature
DCs (iDCs) have high phagocytic capabilities but are poorly
immunogenic as they express low levels ofMHCclass II and the
co-stimulatory receptors CD40, CD80, and CD86 (4). Imma-
tureDCs also play a critical role inmaintaining peripheral T cell
tolerance, which is dependent upon their low expression of co-
stimulatory receptors (4). Maturation of DCs can be triggered
by engagement of receptors such as Toll-like receptors, result-
ing in the up-regulation of co-stimulatory molecules and asso-
ciated loss of phagocytic activity (1). Mature DCs expressing
high levels of co-stimulatory receptors can activate CD8T lym-
phocytes and generate effector cytotoxic T lymphocytes that
possess antiviral and antitumor activity (5–7). DC maturation
involves the activation of several intracellular signaling path-
ways including those of the nuclear factor-B (NF-B) and
MAPKpathways (8–10).NF-Bbelongs to theNF-B/Rel fam-
ily of transcription factors and has been implicated inDCdevel-
opment, maturation, and survival (9, 11). Similarly, the MAP
kinases such as ERK1/2 and p38MAPKhave been implicated in
regulating DC co-stimulatory receptor expression and inflam-
matory cytokine production (8, 12). Furthermore, epigenetic
changes in DC gene expression can influence their maturation
status and subsequent immune function (13, 14). Histone
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deacetylase (HDACs) enzymes (along with histone acetylases)
are responsible for the epigenetic regulation of co-stimulatory
receptor gene expression through deacetylation of histone res-
idues (13–15). Evidence has shown that the intracellular redox
status and reactive oxygen species (ROS) production have a
significant impact on DC functions such as activation, matura-
tion cytokine production, and immunosenescence (16–19).
One of the key antioxidant molecules responsible for mainte-
nance of DC intracellular redox homeostasis is glutathione
(GSH) (16). Cellular GSH levels are mainly determined by the
activity of a basic leucine zipper transcription factor, nuclear
factor-erythroid 2 (NF-E2) p45-related factor-2 (Nrf2), through
transcribing genes involved in GSH biosynthesis such as the
glutamate-cysteine ligase catalytic (GCLC) domain (17, 20).
Nrf2 has been shown to influence DC redox homeostasis and
impact on aspects of DC biology (17, 18, 21, 22). However, it is
not clear whether the effects of Nrf2 deficiency in DC pheno-
type and function can be attributed to a potential lowering of
GSH levels in these cells. Furthermore, the impact of altered
phenotype of Nrf2/ DCs on CD8 T cell stimulatory capacity
has not been examined. Finally, the molecular basis for the
altered co-stimulatory phenotype is unclear. In particular, the
potential effect of loss of Nrf2 on ROS levels, signaling by
theNF-B andMAPKpathways, and involvement ofHDACs in
DCs has not yet been investigated extensively. In this study,
bone marrow-derived Nrf2-deficient iDCs (Nrf2/ iDCs)
demonstrate lower basal levels of GSH and GSH-independent
enhanced co-stimulatory receptor expression, impaired phag-
ocytic function, and enhanced CD8 T cell stimulation capacity
when compared with Nrf2/ iDCs. We also demonstrate
increase in ROS levels and delayed LPS-induced NF-B signal-
ing events without changes in the basal NF-B activity in
Nrf2/ iDCs. Furthermore, loss of Nrf2 affected p42/44
(ERK1/2) but not p38 signaling. Finally, our results provide evi-
dence for HDAC-dependent higher co-stimulatory receptor
expression in Nrf2/ iDCs. Our findings highlight the poten-
tial role of Nrf2 in modulating intracellular ROS, MAPK, and
NF-B signaling and HDAC-dependent co-stimulatory gene
expression in DCs.
EXPERIMENTAL PROCEDURES
Reagents—Fetal calf serum (FCS) and recombinant GM-CSF
were purchased from Invitrogen (Paisley, UK) and PeproTech,
respectively. All other reagents were of analytical grade and
purchased from Sigma-Aldrich (Poole, UK) unless otherwise
stated.
Mice—Nrf2/ and Nrf2/ mice were purchased from
Riken BRC (Ibaraki, Japan) and maintained at the Biomedical
Services Unit, University of Liverpool (23). Mice transgenic for
the H-2Db-restricted TCR- transgene, F5, was a kind gift
from Dr. James Matthews, Cardiff, Wales, UK. Protocols
described herein were undertaken in accordance with criteria
outlined in licenses granted under the Animals (Scientific Pro-
cedures) Act 1986 (PPL 40/2937 and PPL 40/2544).
Generation of BoneMarrow-derivedDCs—Bonemarrow-de-
rived iDCs were generated according to published protocols
(24).
Glutathione Assay—DCs were lysed in 10 mM HCl. 6.5% sal-
icylic acid was added to cell lysates (1:4 v/v), and protein pre-
cipitates were removed by centrifugation. Cell supernatants
were assayed for GSH according to Ref. 25 and normalized to
protein content.
Cell Surface Receptor Expression—DCs were labeled with
CD11cTC (Invitrogen) and CD86FITC, CD40FITC, or
MHC IIPE (BD Biosciences) antibodies for 30 min on ice,
washed, acquired on a BD FACSCanto II flow cytometer (BD
Biosciences), and analyzed using the Cyflogic version 1.2.1 soft-
ware (CyFlo Ltd.). Peripheral T cells from lymph nodes were
labeled with CD8TC (Invitrogen), CD4PE, and CD62LFITC
(BD Biosciences) antibodies and analyzed as above.
DC Endocytosis Assay—DCs were incubated with 0.5 g/ml
DextranFITC (40,000 Mr) (Invitrogen) for 60 min at 37 or 4 °C.
Cells were stained for surface expression of CD11c as described
above and analyzed by flow cytometry.
DC Phagocytosis Assay—Apoptotic thymocytes were gener-
ated from thymi of C57BL/6 mice by treatment with 1 M dex-
amethasone for 18 h. Apoptotic thymocytes were labeled with
the intracellular fluorescent dye, carboxyfluorescein succinimi-
dyl ester (CFSE), and co-cultured with plate-adherent DCs for
2 h at 37 or 4 °C. Cells were stained with CD11cTC prior to
analysis by flow cytometry. Jurkat T cells were fluorescently
labeledwithCFSE, andnecrosiswas induced by snap freezing in
liquid nitrogen. Necrotic cells were co-cultured with DCs as
above and analyzed by flow cytometry.
Intracellular IFN- Staining—F5 CD8 T cells were co-cul-
tured for 72 h with Nrf2/ and Nrf2/ iDCs prepulsed with
1  107 M NP68 peptide. T cells were harvested and co-cul-
tured for 6 h with Nrf2/ mature DCs prepulsed with 1 
107 M NP68. Brefeldin A was added 1 h after start of culture.
Cells were stained with CD8TC followed by fixing, permeabi-
lization, and intracellular staining for interferon- (IFN-
) according to the manufacturer’s instructions (Cytofix/
Cytoperm Plus; BD Biosciences) and analyzed by flow cytometry.
F5 CD8 TCell Proliferation—F5CD8T cell proliferation was
quantified as described in Ref. 26. Briefly, Nrf2/ andNrf2/
iDCswere pulsedwith a dose range of antigenic peptides (NP68
or NP34), washed, and co-cultured with F5 T cells for 72 h.
[3H]Thymidine was added for the last 16 h. Cells were har-
vested onto glass fiber filter mats and read on a scintillation
counter (MicroBeta Trilux; PerkinElmer Life Sciences, Buck-
inghamshire, UK).
Measurement of ROS—Unstimulated or stimulated DCs
were labeled with the fluorescent ROS indicator, dihydro-
ethidium, according to Ref. 27 and analyzed by flow cytometry.
Gel Electrophoresis and Western Blot—Immature DCs
treated with LPS over the indicated time points were lysed, and
20 g of lysate protein/sample was resolved by SDS-PAGE,
transferred to nitrocellulose membranes (GE Healthcare),
blocked, and probed for the indicated proteins using the appro-
priate primary antibodies (phospho-p65, IB, phospho-
ERK1/2, ERK1/2, phospho-p38, and p38, Cell Signaling Tech-
nology; and p65 and actin, Santa Cruz Biotechnologies)
followed by horseradish peroxidase-conjugated secondary
antibodies (Sigma-Aldrich) and visualized using the ECL sys-
tem (PerkinElmer Life Sciences).
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Measurement of NF-B Activity—NF-B activity of iDC
nuclear extractswas determined using the EZ-DetectTMNF-B
p65 transcription factor kit (Pierce Biotechnology) following
the manufacturer’s instructions. Results are expressed as rela-
tive luminescence units.
ELISA—Supernatants were recovered from iDC cultures and
assayed for TNF- using a mouse TNF-Quantikine kit (R&D
Systems) according to the manufacturer’s protocol.
HDAC Activity Assay—HDAC activity of iDC nuclear
extracts was determined using the HDAC assay kit (Millipore)
following the manufacturer’s instructions. Results are
expressed as absorbance at 405 nm (A405).
Statistics—Data were analyzed using the unpaired t test, one-
way analysis of variance, and the Mann-Whitney U test
RESULTS
Loss of Nrf2 Results in Altered Phenotype and Antigen Cap-
ture Function of DCs—Toevaluate the role ofNrf2 in regulating
the phenotype and function of iDCs, we compared the matura-
tion states of Nrf2/ and Nrf2/ iDCs in addition to meas-
uring endocytic and phagocytic function.Maturation is accom-
panied by an increase in the proportion of DCs that express
higher levels of co-stimulatory molecules (1). Immature DCs
are composed of subpopulations that express either high or low
levels of co-stimulatory molecules (Fig. 1A). Flow cytometric
analysis of iDCs demonstrate that the proportion of iDCs that
express high levels of CD86, CD40, and MHC II was signifi-
cantly increased in the Nrf2/ iDCs in comparison with the
Nrf2/ iDCs as shown in Fig. 1A (CD86, 29.75 versus 12.5%,
p  0.05; CD40, 26.5 versus 11.75%, p  0.05; MHC II, 30.5
versus 10.5%, p  0.05). DC maturation is accompanied by a
diminished capacity for phagocytosis and endocytosis. As
Nrf2/ iDCs exhibited a more mature phenotype, we tested
whether they also have impaired antigen capture functions. As
shown in Fig. 1B, in comparison with Nrf2/ iDCs, Nrf2/
iDCs had a significantly lower capacity to phagocytose apopto-
tic cells (4.7 versus 2.8-fold increase over baseline, p 0.05) and
necrotic cells (4.8- versus 1.7-fold increase over baseline, p 
0.05). Endocytic capacity of Nrf2/ iDCs was also impaired
when compared with the Nrf2/ iDCs (45.1 versus 88.1%, p
0.05), as shown in Fig. 1C. These results indicate that loss of
Nrf2 affects iDC maturation state and concomitant antigen
capture functions.
Dysregulation in Phenotype and Function of Nrf2/ iDCs Is
Not a Direct Consequence of Lower GSH Levels—Nrf2 is a crit-
ical regulator of GSH biosynthesis (20), and loss of Nrf2 is
hypothesized to result in lowered intracellular GSH inDCs.We
therefore measured basal levels of GSH and show that Nrf2/
iDCs have up to 33% reduction in GSH levels relative to
Nrf2/ iDCs (p 0.05) (Fig. 2A). To test whether the changes
in phenotype and function of Nrf2/ iDCs could be due to
lowered GSH levels, buthionine sulfoximine (BSO), a potent
inhibitor of the glutamate-cysteine ligase catalytic domain (an
essential enzyme involved in GSH biosynthesis) (28), was used
to reduce GSH levels and assess effects on phenotype and func-
tion in Nrf2/ iDCs. Fig. 2B demonstrates that up to 77%
reduction in basal GSH levels can be achieved through treat-
ment of Nrf2/ iDCs with BSO (p 0.05). When the expres-
sion levels ofMHC II, CD86, and CD40 were analyzed on BSO-
treated iDCs, no detectable changes in surface expression of
these receptors could be observed (Fig. 2C). Furthermore, low-
ering GSH levels did not affect either the phagocytic or the
endocytic functions of iDCs (Fig. 2, D and E). These results
suggest that although loss ofNrf2 results in reducedGSH levels,
the changes in phenotype and function ofNrf2/ iDCs cannot
be attributed to the lowered basal GSH.
Increased Co-stimulatory Receptor Expression of Nrf2/
iDCs Is Associated with Enhanced Antigen-specific CD8 T Cell
Stimulatory Capacity—Immature DCs expressing low levels of
co-stimulatory molecules are unable to stimulate a fully com-
petent antigen-specific CD8 T cell response (4). Given that
Nrf2/ iDCs have elevated expression of CD86, CD40, and
MHC II, we postulated that these iDCs would be capable of
inducing an antigen-specific CD8 T cell response.
To address this, we utilized a TCR transgenic mouse model,
F5, wherein the CD8 T cells express a T cell receptor (F5 TCR)
that recognizes an antigenic peptide, NP68, when presented by
DCs (29). The functional consequence of changes in DC co-
stimulatory receptor expression can be assessed by the ability of
NP68-bearing DCs to stimulate F5 CD8 T cell proliferation.
FIGURE 1. Loss of Nrf2 leads to dysregulation inmultiple DC functions. A,
Nrf2/ andNrf2/ iDCswere labeledwith antibodies againstMHC II, CD86,
and CD40 co-stimulatory receptors. Co-stimulatory receptor expression was
determinedby flowcytometry. Thepercentageof iDCs expressinghigh levels
of co-stimulatory receptors is indicated above the marker. Representative
histograms are presented with average percentage S.D. Statistical signifi-
cance was tested by unpaired Student’s t test (*, p 0.05). Data are derived
from four independent experiments. B, Nrf2/ and Nrf2/ iDCs were co-
cultured with CFSE-labeled apoptotic thymocytes or necrotic Jurkat cells at
37 °C for 2 h. DC phagocytic capacity was measured by flow cytometry as an
increase in CFSE levels when compared with corresponding 4 °C baseline
control samples.Data areexpressedas average -fold changesS.E. Statistical
significancewas testedbyMann-WhitneyU test (*,p0.05). Data are derived
from five independent experiments. C, endocytic capacity was measured by
incubating Nrf2/ or Nrf2/ iDCs cells with DextranFITC for 60min at 37 °C.
DextranFITC uptake by iDCs was assessed by flow cytometry. Data are pre-
sented as average percentage of uptake  S.D. Statistical significance was
tested by unpaired Student’s t test (*, p  0.05). Data are derived from four
independent experiments.
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Nrf2/ iDCs pulsed with increasing doses of NP68 did not
induce specific F5 CD8 T cell proliferation until 10 nM NP68
(Fig. 3A, panel i). A higher dose of NP68 (100 nM) induced
greater proliferation. In contrast, Nrf2/ iDCs were able to
induce significant F5 CD8 T cell proliferation even at 1 nM
NP68 (Fig. 3A,panel i) and a 3-to-10-fold higher degree ofT cell
proliferation when compared with Nrf2/ iDCs at all NP68
doses (Fig. 3A, panel i, p  0.05). As with the phenotype and
antigen capture functions, lowering ofGSHdid not increase the
ability of Nrf2/ iDCs to stimulate antigen-specific CD8 T
cells (Fig. 3A, panel ii). Following primary antigen-specific acti-
vation, CD8 T cells develop into IFN--producing effectors
(30). Our results indicate that Nrf2/ iDCs can generate
between 1.4- and 2.4-fold more effectors from naive F5 CD8 T
cells when compared with Nrf2/ iDCs (Fig. 3B). These
results highlight the association between increased co-stimula-
tory marker expression of Nrf2/ iDCs and the ability to
induce enhanced CD8 T cell proliferation and acquisition of
effector function. The induction of CD8 T cell tolerance by
iDCs is largely due to the presentation of self-peptides (31). An
altered peptide ligand, termedNP34, binds to the F5TCRwhen
presented by iDCs, does not activate naive F5 CD8 T cells, and
simulates, to a degree, the interaction between self-peptides
with TCRs on naive T cells (32, 33). NP34-pulsedNrf2/ iDCs
did not induce significant F5 CD8 T cell proliferation even at
doses as high as 1 M (Fig. 3C, panel i). In contrast, NP34 pres-
entation by Nrf2/ iDCs resulted in a 2-fold increase in pro-
liferation of F5 CD8 T cells at 10 nM NP34 and above when
compared with unpulsed iDCs (Fig. 3C, panel i, p 0.05 for all
NP34 doses). As with T cell responses with NP68, depletion of
GSH from Nrf2/ iDCs does not recapitulate the T cell
responses observed with NP34-pulsed Nrf2/ iDCs (Fig. 3C,
panel ii). The ability to provoke T cell responses by self-peptide
bearing Nrf2/ iDCs could lead to inappropriate T cell acti-
vation in vivo. To investigate this possibility, we compared the
levels of CD62L, amarker of T cell activation in the lymph node
T cells from Nrf2/ and Nrf2/ mice. T cell activation
results in the down-regulation of CD62L (34). Our results dem-
onstrate that T cells from Nrf2/mice manifest signs of low-
level T cell activation with a small but consistent reduction in
CD62L expression when compared with their Nrf2/ coun-
terpart (Fig. 3D).
Loss of Nrf2 Results in Increased ROS Levels in Immature
DCs—Elevations in DC ROS levels have been shown to
enhance co-stimulatory receptor expression and maturation
(19). Nrf2 signaling increases transcription of antioxidant
genes that counter elevations in intracellular ROS (20). We
therefore examined ROS levels in Nrf2/ and Nrf2/
iDCs basally and in response to the oxidative stress inducer
hydrogen peroxide (H2O2) and the Toll-like receptor agonist
LPS using the fluorescent ROS indicator, dihydroethidium.
As demonstrated in Fig. 4, Nrf2/ iDCs had significantly
higher basal ROS levels in comparison with Nrf2/ iDCs
(mean fluorescence intensity 1341 versus 833.5, p  0.05).
Furthermore, Nrf2/ iDC ROS level were significantly
increased in comparison with their wild type counterpart
following treatment with H2O2 (mean fluorescence intensity
2159 versus 1482, p  0.05) and LPS (mean fluorescence
intensity 1557 versus 1026, p  0.05). Taken together, these
results suggest that loss of Nrf2 impairs the capacity of iDCs
to maintain redox homeostasis.
Elevated ROS Levels in Nrf2-deficient DCs Do Not Affect
Basal Nuclear NF-B Activity—Elevated ROS levels in DCs
have been associated with alterations in NF-B signaling (35).
We examined basal and LPS-induced phosphorylation of p65
and degradation of IB to investigate the effect of Nrf2 defi-
ciency on NF-B signaling pathway. These events are essential
upstream events required for NF-B activation (36). Although
there were no basal differences in phosphorylated p65, LPS-
induced phosphorylation of p65 was impeded in the Nrf2/
iDCs when compared with the Nrf2/ iDCs (Fig. 5A). In
Nrf2/ iDCs, an increase in p65 phosphorylation can be
detected at 10min, peaking at 30min, followed by a decrease to
basal levels at 120 min after stimulation (Fig. 5A). In contrast,
no increases in p65 phosphorylation can be detected inNrf2/
iDCs (Fig. 5A) at any of the time points. Similarly, as can be seen
in Fig. 5B, the basal (at 0min) levels of IBwere comparable in
both cell types. However, upon stimulationwith LPS, IB deg-
FIGURE2.Dysregulation in functionofNrf2/DCisnotaconsequenceof
lowerGSH levels.A and B, GSH levelsweremeasured inNrf2/ andNrf2/
iDC (A) orNrf2/ iDCsuntreated (Control) or treatedwithBSO (100M) (B) for
24 h. Data are presented as average percentage (when compared with
Nrf2/ or untreated iDCs)  S.D. Statistical significance was tested by
unpaired Student’s t test (*, p 0.05). Data are derived from five independent
experiments. C, immature Nrf2/ DCs untreated or treated with BSO were
labeled with antibodies against MHC II, CD86, and CD40 co-stimulatory
receptors. Co-stimulatory receptor expression was determined by flow
cytometry. Histogram overlays show fluorescence intensity of respective co-
stimulatory receptors and are representative of four independent experi-
ments. D, immature Nrf2/ DCs untreated or treated with BSO were co-cul-
turedwithCFSE-labeledapoptotic thymocytesor necrotic Jurkat cells at 37 °C
for 2 h. DC phagocytic capacity was measured by flow cytometry as an
increase in CFSE levels when compared with corresponding 4 °C baseline
control samples. Data are presented as average -fold changes S.E. Data are
derived from five independent experiments. E, endocytic capacity wasmeas-
ured by incubating Nrf2/ iDCs that were untreated or treated with BSO
with DextranFITC for 60 min at 37 °C. DextranFITC uptake by DCs was assessed
by flow cytometry. Data are derived from four independent experiments and
presented as average percentage of uptake S.D.
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radation can be seen as early as 10min, progressing to total loss
of IB at 60 min in Nrf2/ iDCs, whereas in Nrf2/ iDCs,
IB degradation was delayed in onset (at 15 min) and incom-
plete in extent with residual IB being detected at 90min after
stimulation (Fig. 5B). We examined the basal nuclear NF-B
(p65) activity and demonstrate that there are no significant
basal differences in NF-B activity between Nrf2/ and
Nrf2/ iDCs (Fig. 5C). Taken together, these results suggest
that although an increase in ROS levels in Nrf2-deficient iDCs
may affect upstream elements of theNF-Bpathway (phospho-
rylation of p65 and IB degradation), it however did not affect
basal NF-B activity.
Elevated ROS Levels in Nrf2-deficient DCs Do Not Affect
MAPK-mediated Co-stimulatory Receptor Expression—Altera-
tions in ROS levels in DCs are associated with changes in
ERK1/2 and p38 MAPK signaling pathways (8). Activation of
MAPK pathways by stimuli such as LPS results in phosphory-
lation of ERK1/2 and p38 MAPK (37). The level of phosphor-
ylated ERK1/2 was slightly higher in Nrf-2/ iDCs in compar-
ison with Nrf2/ iDCs both basally and upon LPS stimulation
(Fig. 6A, panel i). Furthermore, Nrf2/ iDCs exhibited
enhanced phosphorylation kinetics of ERK1/2 in response to
LPS in comparison with their wild type counterpart. The onset
of LPS-induced phosphorylation of ERK1/2 was observed at 10
min inNrf2/when compared with 15min for Nrf2/ iDCs.
FIGURE 3. IncreasedT cell stimulatory capacity ofNrf2/ iDCs.A, Nrf2/ andNrf2/ iDCs (panel i) and untreated (Control) or BSO (100M for 24 h) (panel
ii)-treated Nrf2 / iDCs were pulsed with increasing concentrations of NP68 antigenic peptide, and DCs were then co-cultured with F5 CD8 T cells for 72 h.
[3H]Thymidine (3H-Thy) was added for the last 16 h. Proliferation of T cells was determined by scintillation counting of incorporated [3H]thymidine. Data are
presented as average [3H]thymidine scintillation counts S.D. Statistical significancewas tested by one-way analysis of variance (*, p 0.05). Data are derived
from four independent experiments.B, naive F5CD8Tcellswere co-culturedwithNrf2/orNrf2/ iDCs asdescribedunder “Experimental Procedures.” Total
numbers of IFN--producing effector T cells were quantified by intracellular cytokine staining. C, Nrf2/ and Nrf2/ iDCs (panel i) and untreated or BSO-
treated Nrf2/ iDCs (panel ii) were pulsedwith increasing concentrations of NP34 partial agonist. DC-induced T cell proliferation was determined as in panel
A.D, CD62L expression on CD4 and CD8 T cells from the lymph nodes of Nrf2/ andNrf2/micewas determined by flow cytometry. Histogramoverlays are
representative of three independent experiments.
FIGURE 4. Loss of Nrf2 elevates intracellular ROS levels. Nrf2/ and
Nrf2/ iDCs were untreated (basal) or treated with LPS (1 g/ml) or H2O2
(1 mM) for 10 min at 37 °C. Cells were then incubated with the ROS indica-
tor dihydroethidium before analysis by flow cytometry. Data points rep-
resent mean fluorescence intensity of six separate measurements from
two independent experiments. The horizontal line represents the mean.
Statistical significancewas tested by unpaired Student’s t test (*, p 0.05).
FIGURE 5. Loss of Nrf2 perturbs NF-B signaling in iDCs. Nrf2/ and
Nrf2/ iDCs were treated with LPS (1 g/ml) for the indicated times, and
whole cell lysates were subjected to SDS-PAGE. A and B, the levels of phos-
phorylation of p65 (p-p65) (A) andof IB levels (B) were assessedbyWestern
blotting. Data are representative of three independent experiments.C, NF-B
activity in the nuclear lysates of Nrf2/ andNrf2/ iDCs wasmeasured and
presented as dot plots with each dot representing mean relative lumines-
cence units (RLU) (from triplicates). Data are from six independent experi-
ments. The horizontal lines indicate means for each group.
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To investigate whether this change in basal ERK1/2 phospho-
rylation contributes to the enhanced co-stimulatory phenotype
in Nrf2/ iDCs, we treated Nrf2/ and Nrf2/ iDCs with
the ERK inhibitor, PD98059, and assessed its effect on iDC co-
stimulatory expression. ERK inhibition did not reverse the
enhanced expression ofMHC II andCD86 inNrf2/ iDCs but
rather caused a slight increase (Fig. 6A, panel ii) as reported
previously for human DCs (8). This suggests that enhanced co-
stimulatory receptor expression in Nrf2/ iDCs is not
dependent on ERK1/2 activity. We next assessed the levels of
phospho-p38 in Nrf2/ and Nrf2/ iDC lysates. There were
no detectable differences in phospho-p38 between the two cell
types (basal or LPS-induced), indicating that p38 MAPK path-
way may not be affected by the loss of Nrf2 (Fig. 6B).
Enhanced Co-stimulatory Receptor Expression of Nrf2/
iDCs Is Dependent on Histone Deacetylase Activity—HDAC is
involved in regulating DC differentiation, maturation, cytokine
production, and immune function (13, 14). To investigate
whether enhanced co-stimulatory receptor expression of
Nrf2/ iDCs was dependent on HDAC activity, valproic acid
(VPA), an HDAC inhibitor (38), was used. VPA at a concentra-
tion of 100 g/ml reduces iDC HDAC activity by 50% (data
not shown). As shown in Fig. 7A, VPA caused a reduction in
MHC II and CD86 co-stimulatory expression levels in the
Nrf2/ iDCs (MHC II, 35.2 versus 18.7%, p 0.05; CD86, 33.7
versus 19.4% p  0.05). In addition to altered co-stimulatory
receptor expression, it has been previously shown that secre-
tion of TNF- is also dysregulated in Nrf2/ iDCs (21). We
therefore were interested in whether TNF- secretion is sub-
ject to modulation by HDAC inhibition in Nrf2/ iDCs.
Untreated Nrf2/ iDCs secrete measurable quantities of
TNF-. However, inhibition of HDACwith VPA did not signif-
icantly alter TNF- secretion (Fig. 7B). To examinewhether the
increased co-stimulatory receptor expression is accompanied
by changes in HDAC activity, we measured HDAC activity in
the nuclear lysates of Nrf2/ and Nrf2/ iDCs. Although
there is a marginal increase in HDAC activity in the Nrf2/
iDCs when compared with Nrf2/ iDCs (0.80  0.08 versus
0.74  0.09 respectively), this was not statistically significant
(p 0.08) (Fig. 7C). Despite the absence of amarked increase in
theHDACactivity in theNrf2/ iDCs, our results suggest that
the enhanced co-stimulatory expression of Nrf2/ iDCs is
nevertheless dependent on HDAC activity.
DISCUSSION
Our present study investigated the role of Nrf2 in DC
immune function and intracellular signaling pathways. Studies
have shown that the co-stimulatorymolecules CD86 andMHC
II are elevated in Nrf2/ iDCs, and our results support these
findings (17, 21). We also found a marked increase in CD40
expression in the Nrf2/ iDCs, which has not been docu-
mented previously. The difference in findings between the two
studies could be due to some differences in DC culture meth-
ods. Previous studies using Nrf2-deficient mice have shown
lowered GSH levels in a variety of cell types, but GSH levels in
Nrf2/DCs have not beenmeasured (20, 39, 40). Our findings
demonstrate that Nrf2/ iDCs have lowered GSH levels, but
this is not sufficient to cause the altered phenotype in Nrf2/
iDCs. This is consistent with other studies that found that the
enhanced co-stimulatory expression Nrf2/ iDCs could not
be reversed by repletingGSHusing theGSHprecursorN-acetyl
cysteine (21). Amajor function of iDCs is to take up antigens via
FIGURE 6. Effects of Nrf2 loss on MAPK signaling in DCs. Nrf2/ and
Nrf2/ iDCs were treated with LPS (1 g/ml) for the indicated time points,
and whole cell lysates were subjected to SDS-PAGE. A, panel i, phosphoryla-
tion of ERK1/2 (p-ERK1/2) assessed byWestern blotting. B, phosphorylation of
p38 MAPK (p-p38) assessed by Western blotting. Data are representative of
three independent experiments. A, panel ii, Nrf2/ and Nrf2/ iDCs were
untreated or treated with 50M PD98059 (MEK1 inhibitor/ERK inhibitor). Co-
stimulatory receptor expressionwas determined by flow cytometry. Data are
representative of three independent experiments.
FIGURE 7. Histone deacetylase function is required for co-stimulatory
receptor expression in Nrf2/ iDCs. A, Nrf2/ iDCs were treatedwith the
HDAC inhibitor, valproic acid (100 g/ml) (VPA), for 72 h and labeled with
antibodies against MHC II and CD86. The percentage of DCs expressing high
levels of co-stimulatory receptors is indicated above themarker. Representa-
tive histograms are presented with average percentage  S.D. Data were
derived from four independent experiments. B, Nrf2/ iDCs were untreated
or treatedwith VPA for 24 h, supernatantswere collected, and levels of TNF-
were measured. Data are presented as average pg/ml  S.D. and derived
from three independent experiments. C, HDAC activity was measured in
nuclear lysates fromNrf2/ andNrf2/ iDCs.Data arepresentedas average
absorbance at 405 nm  S.D. and derived from three independent experi-
ments. OD, optical density.
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phagocytic and endocytic processes, critical for initiation of T
cell immune response and for induction of T cell tolerance
(1–3). As DCsmature, they lose their endocytic and phagocytic
capacity, which correlates closely with higher expression of co-
stimulatory molecules. Both endocytic and phagocytic func-
tions were impaired in Nrf2/ iDCs. Defects in endocytic/
phagocytic function of DCs are associated with systemic lupus
erythematosus andGaucher disease (41, 42). It is intriguing that
aged Nrf2/ female mice develop systemic lupus erythemato-
sus-like disease. It would therefore be useful to examine Nrf2
function in DCs from systemic lupus erythematosus patients to
clarify a role for Nrf2 in DC phagocytosis and pathogenesis of
systemic lupus erythematosus.
Generation of functional cytotoxic T lymphocytes from
naive CD8 T cells requires co-stimulatory and T cell receptor
signals (5–7). CD8 T cells cannot be fully stimulated by imma-
ture DCs that normally express low amounts of co-stimulatory
molecules (4). The implications of the enhanced co-stimulatory
receptor expression by Nrf2/ iDCs on antigen-specific T cell
outcomes have not been explored. In this study, we have made
a clear demonstration that Nrf2/ iDCs presenting the anti-
genic peptides can induce substantial CD8 T cell proliferation
in the absence of any further maturation or co-stimulatory sig-
naling. Additionally, we showed that the CD8 T cells activated
by the Nrf2/ iDCs develop effector functions. Under normal
conditions, presentation of self-peptides to T cells by iDCs that
express low levels of co-stimulatory molecules leads to the
induction of T cell tolerance (31). The potential ability of
Nrf2/ iDCs to stimulate enhancedCD8T cell activation sug-
gests that these DCs may not be tolerogenic. To test this possi-
bility, we used a partial agonist as a surrogate self-peptide to
assess the ability of Nrf2/ iDCs to stimulate CD8 T cells and
discovered that these iDCs can induce CD8 T cell activation.
Furthermore, we found lowered CD62L expression in the
Nrf2/ peripheral lymph node T cells, indicating that they
have been undergoing low-level activation, presumably
through interaction with DCs in the lymph nodes. It has been
shown thatDCs bearing self-peptides can deliver low-level acti-
vatory signals to T cells through the TCR (43). These low-level
signals are important for T cell survival in the host animal (44).
It is possible that the elevated co-stimulatory receptor expres-
sion by theNrf2/ iDCs augments these low-level TCR signals
and causes a slight but significant activation of interacting T
cells in vivo. These findings raise the possibility that Nrf2 could
play an important role in the maintenance of peripheral T cell
tolerance by iDCs.
Changes in ROS levels in DCs have been implicated in alter-
ing DC co-stimulatory expression, maturation, and subsequent
immune response elicited (17, 19). Our results suggest that the
enhancedmaturation phenotype of Nrf2/ iDCs is associated
with increased basal ROS levels. In support of our finding,
increases in basal H2O2 levels have been observed in Nrf2-de-
ficient DCs (17). It would be interesting to test whether antiox-
idants could dampen ROS levels and reverse changes in co-
stimulatory phenotype and function of Nrf2/ iDCs.
NF-B is involved in DC development, survival, andmatura-
tion (9, 11). NF-B is activated by a variety of stimuli such as
LPS and oxidative stress (36). Upon activation, upstream IB
kinase (IKK) complexes are activated, which in turn phospho-
rylate IB, resulting in its ubiquitination and subsequent pro-
teasomal degradation. This facilitates NF-B translocation into
the nucleus, where it can transcribe genes involved in the
immune response (36). ROS levels have been shown to both
induce and repress NF-B signaling depending on the cell type
(45, 46). Interestingly, our results revealed delayed kinetics of
LPS-induced phosphorylation of p65 and IB degradation in
Nrf2/ DCs. Elevated ROS levels in Nrf2/ iDCs could
induce modifications in the cysteine residues in upstream
kinases, namely IKK, resulting in its inactivation and inability
to phosphorylate phospho-65 and IB (47). However, we did
not find any difference in basal NF-B activation. This is con-
sistent with previous studies inNrf2-deficientmice whereby no
differences in basal NF-B activation in lung lysates were
observed between Nrf2/ and Nrf2/ mice (22, 39). How-
ever, it appears that changes to upstream elements of the
NF-B pathway in Nrf2/ iDCs do not translate to alterations
in nuclear NF-B. Increased intracellular ROS and other stim-
uli such as LPS also induce activation of MAPKs, resulting in
increased DC co-stimulatory expression, cytokine production,
and capacity to stimulate T cells in secondary lymphoid organs
(12). Although inhibitor studies have implicated ERK and p38
MAPK in CD86 and HLA-DR expression in human DCs under
conditions where changes in ROS have been induced by chem-
ical sensitizers, our results show that ERK and p38 MAPK are
not responsible for the altered phenotype in the Nrf2-deficient
DCs (8). The effect of chronic elevated basal levels of ROS in the
intracellular environment of Nrf2-deficient DCs could be dif-
ferent from transient ROS elevations induced by chemical
sensitizers.
HDAC has been associated with modulating DC differentia-
tion, co-stimulatory expression, cytokine production, and
immunogenicity (13). Our finding that the Nrf2-deficient co-
stimulatory phenotype can be reversed by HDAC inhibition
places HDACs as potential targets of Nrf2 function. Although
the HDAC activity in Nrf2/DCs tended to be higher than in
the wild type DCs, this difference was not statistically signifi-
cant. However, it is possible that such small differences could
lead to significant biological outcomes. In particular, a margin-
ally higher HDAC function can lead to cumulative effects over
time andmay drive epigenetic changes, thus altering co-stimu-
latorymolecule expression onDCs. Interestingly, dysregulation
of HDAC functions has been associated with diseases such as
cancer, chronic obstructive pulmonary disease, and asthma in
which the pathology is associated with redox disequilibrium,
implicating the link between redox status and HDAC (38, 48).
Further investigation into the molecular pathways that lead
from Nrf2 activity to ROS through to HDAC is merited. The
availability of pharmaceuticals that target HDACs for thera-
peutic indications opens up the possibility of using such thera-
peutic strategies to modulate DC functions (14, 49, 50) in dis-
eases that are associated with altered Nrf2 function.
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